Single-institution experience of 500 pulmonary resections guided by intraoperative molecular imaging.

ABSTRACT:

Objective

Intraoperative molecular imaging (IMI) using tumor-targeted optical contrast agents can improve thoracic cancer resections. There are no large-scale studies to guide surgeons in patient selection or imaging agent choice. Here, we report our institutional experience with IMI for lung and pleural tumor resection in 500 patients over a decade.

Methods

Between December 2011 and November 2021, patients with lung or pleural nodules undergoing resection were preoperatively infused with 1 of 4 optical contrast tracers: EC17, TumorGlow, pafolacianine, or SGM-101. Then, during resection, IMI was used to identify pulmonary nodules, confirm margins, and identify synchronous lesions. We retrospectively reviewed patient demographic data, lesion diagnoses, and IMI tumor-to-backgr

SUBMITTER: Kennedy GT 

PROVIDER: S-EPMC10311075 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature